Analytical Data
-
Gene name
CTLA4
- Application
-
Alternative Names
CD152; CELIAC3; CTLA4; GSE; IDDM12; Celiac Disease 3; Cytotoxic T-lymphocyte protein 4
-
Species
Mouse
-
Source
E. coli
-
Tag
Two N- s, His- & SUMO-
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P09793
-
Expression Region
Val45~Ser185
-
Molecular Weight
32kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) plays a crucial role in the regulation of immune responses and is a key negative regulator of T cell activation. Initially discovered as a molecule that inhibits T cell proliferation and cytokine production, CTLA-4 has become a significant focus of immunotherapy research, particularly in cancer treatment. Its mechanism involves competing with CD28 for binding to CD80 and CD86, which leads to decreased signaling for T cell activation. The advent of monoclonal antibodies targeting CTLA-4, such as ipilimumab, has revolutionized cancer therapy, demonstrating the potential of immune checkpoint inhibitors in enhancing anti-tumor immunity. Research into CTLA-4 recombinant proteins has provided insights into the intricate balance of immune regulation and has facilitated the development of novel therapeutic strategies. These recombinant proteins are utilized in various studies to explore their functional roles, therapeutic applications, and to understand the underlying mechanisms of immune tolerance and activation, further positioning CTLA-4 as a pivotal player in the landscape of immunological research and cancer therapy.
